AI Article Synopsis
- Embryonic and tumour cells develop mechanisms to shield themselves from harmful substances, leading to multidrug resistance (MDR) that hinders cancer treatment effectiveness.
- Cytochromes P450 (CYPs), especially CYP2C and CYP2J, are significant in drug metabolism, impacting the effectiveness of around 20% of essential medications.
- Recent studies suggest that peroxisome proliferator-activated receptor α (PPARα) could regulate CYP enzymes, presenting a potential avenue to combat MDR in cancer patients.
Article Abstract
Embryonic and tumour cells are able to protect themselves against various harmful compounds. In human pathology, this phenomenon exists in the form of multidrug resistance (MDR) that significantly deteriorates success of anticancer treatment. Cytochromes P450 (CYPs) play one of the key roles in the xenobiotic metabolism. CYP expression could contribute to resistance of cancer cells to chemotherapy. CYP epoxygenases (CYP2C and CYP2J) metabolize about 20% of clinically important drugs. Besides of drug metabolism, CYP epoxygenases and their metabolites play important role in embryos, normal body function, and tumors. They participate in angiogenesis, mitogenesis, and cell signaling. It was found that CYP epoxygenases are affected by peroxisome proliferator-activated receptor α (PPARα). Based on the results of current studies, we assume that PPARs ligands may regulate CYP2C and CYP2J and in some extent they may contribute to overcoming of MDR in patients with different types of tumours.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492927 | PMC |
| http://dx.doi.org/10.1155/2012/656428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!